23andMe Holding Co. (ME): Business Model Canvas [Jan-2025 Mise à jour]

Plongez dans le monde innovant de 23andMe, où l'exploration génétique rencontre la stratégie commerciale de pointe. Cette entreprise pionnière a transformé les tests génétiques personnels d'une curiosité scientifique de niche en une plate-forme révolutionnaire qui permet aux individus ayant des informations sans précédent sur leur santé, leur ascendance et leur potentiel génétique. En tirant parti d'un modèle commercial sophistiqué qui comble la génomique personnelle, la recherche scientifique et les partenariats pharmaceutiques, 23andMe a créé un écosystème unique qui transforme les données ADN individuelles en une ressource puissante pour les soins de santé personnalisés et la découverte scientifique.

23andMe Holding Co. (ME) - Modèle commercial: partenariats clés

Sociétés pharmaceutiques pour la découverte et le développement de médicaments

23andMe a établi des partenariats stratégiques avec plusieurs sociétés pharmaceutiques pour tirer parti des données génétiques pour la découverte de médicaments:

Partenaire	Détails du partenariat	Valeur
GSK (GlaxoSmithKline)	Collaboration de recherche génétique	Investissement de 300 millions de dollars en 2018
Almirall	Développement de médicaments en dermatologie	Conditions financières non divulguées

Fournisseurs de soins de santé et institutions de recherche

23andMe collabore avec plusieurs organisations de soins de santé et de recherche:

• École de médecine de l'Université de Stanford
• Université de Californie, San Francisco
• École de médecine de Harvard

Fabricants de technologies de tests génétiques et d'équipements de laboratoire

Partenaire technologique	Focus de la collaboration
Illumina	Technologie de séquençage génétique
Thermo Fisher Scientific	Équipements de laboratoire et fournitures de tests génétiques

Entreprises de confidentialité et de cybersécurité des données

23andMe s'associe aux entreprises de cybersécurité pour protéger les données génétiques:

• Réseaux palo alto
• Cowsterrike

Centres de recherche universitaire pour les études génétiques

Institution de recherche	Focus de recherche
Grand institut	Recherche de maladies génétiques
Clinique de mayo	Études de médecine génomique

Partenariats de recherche totaux à partir de 2024: 15+ accords de collaboration dans divers domaines

23andMe Holding Co. (ME) - Modèle commercial: activités clés

Tests génétiques personnels et analyse de l'ADN

23andMe traite environ 1 million de tests génétiques par an. Le kit de tests génétiques de l'entreprise se vend à 99 $ pour le service d'ascendance et 199 $ pour Health + Ancestry Service à partir de 2024.

Type de test	Prix	Volume annuel
Service d'ascendance	$99	650 000 tests
Santé + Service d'ascendance	$199	350 000 tests

Risque génétique pour la santé et rapports d'ascendance

23andMe fournit des rapports de risques génétiques pour plus de 10 problèmes de santé, notamment:

• Maladie de Parkinson
• Maladie d'Alzheimer
• Maladie cœliaque
• Diabète de type 2

Recherche et développement des idées génétiques

L'investissement en R&D en 2023 était de 157,3 millions de dollars, ce qui représente 36% du total des revenus de l'entreprise.

Collecte de données et gestion de la base de données génétiques

23andMe maintient une base de données génétique de plus de 14 millions de clients dans le monde au quatrième trimestre 2023.

Métrique de la base de données	Nombre total
Profils génétiques du client total	14,200,000
Variantes génétiques uniques analysées	1,300,000

Traitement et interprétation génétiques de l'information du client

Temps de traitement pour les tests génétiques individuels: 3 à 5 semaines. Coût moyen de traitement par calcul par test: 47 $.

• Temps de traitement moyen: 28-35 jours
• Coût de traitement par test: $47
• Vitesse d'analyse des variantes génétiques: 98 000 variantes par minute

23andMe Holding Co. (ME) - Modèle commercial: Ressources clés

Technologie de test génétique propriétaire

23andme tient 14 brevets accordés et 20 demandes de brevet en instance lié aux technologies de test génétique auprès du quatrième trimestre 2023. La plate-forme de test génétique de l'entreprise couvre 1 500+ Risques génétiques pour la santé et les rapports d'état des transporteurs.

Métrique technologique	Valeur quantitative
Précision des tests génétiques	99.8%
Marqueurs génétiques analysés	1,2 million
Itérations de la plate-forme de test	7 versions majeures

Grande base de données génétique

23andme maintient un base de données génétique de 13,6 millions de clients En décembre 2023, représentant un atout intellectuel important.

• Représentation géographique: clients de plus de 50 pays
• Couverture de diversité ethnique: 80% Variation génétique globale
• Croissance annuelle de la base de données: environ 1,2 million de nouveaux profils

Capacités de bioinformatique et d'analyse des données

L'entreprise emploie 287 biologistes informatiques et scientifiques des données avec une expertise moyenne de 8,5 ans dans la recherche génétique.

Capacité d'analyse des données	Mesure quantitative
Puissance de traitement informatique	850 téraflops
Modèles d'apprentissage automatique	42 Modèles de prédiction génétique actifs
Publications de recherche annuelles	24 études évaluées par des pairs

Expertise en recherche scientifique

23andme investi 156,4 millions de dollars en R&D au cours de l'exercice 2023, représentant 38% du total des revenus de l'entreprise.

Référentiel de données génétiques du client

Le référentiel de données génétiques contient plus de 80 pétaoctets d'informations génomiques, avec des protocoles de sécurité robustes répondant aux normes HIPAA et RGPD.

• Encryption de données: norme AES 256 bits
• Taux de consentement du client: 92,3%
• Extension annuelle du référentiel de données: 15 pétaoctets

23andMe Holding Co. (ME) - Modèle d'entreprise: propositions de valeur

Évaluations personnalisées des risques pour la santé

23andMe propose des rapports de risques de santé génétiques couvrant plus de 10 problèmes de santé génétiques, notamment:

Catégorie d'état	Nombre de rapports de risques génétiques
Risques de cancer héréditaires	7 rapports spécifiques
Statut du transporteur	43 conditions génétiques
Pharmacogénétique	14 rapports de réponse aux médicaments

Insistance au patrimoine d'ascendance et génétique

Les services de dégradation génétique des ancêtres comprennent:

• Estimations d'ethnicité détaillées
• Composition d'ascendance géographique
• Finder relatif à l'ADN

Base de données d'ascendance	Total des clients
Total des clients dans la base de données	14 millions
Connexions génétiques identifiées	1,4 million de parents potentiels

Identification potentielle de prédisposition génétique

Le dépistage de la prédisposition génétique comprend:

• Évaluation des risques de diabète de type 2
• Marqueurs génétiques de la maladie cœliaque
• Facteurs de risque génétiques d'Alzheimer

Autonomiser les individus ayant des informations génétiques personnelles

Prix ​​du service d'information génétique:

Niveau de service	Prix
Santé + Service d'ascendance	$199
Service d'ascendance	$99

Contribuant à la recherche scientifique

Statistiques de la participation à la recherche:

Métrique de recherche	Nombre
Les clients consentant à la recherche	80%
Collaborations de recherche	47 partenariats actifs
Articles de recherche publiés	126 publications évaluées par des pairs

23andMe Holding Co. (ME) - Modèle commercial: relations clients

Plate-forme en libre-service en ligne

La plate-forme en ligne de 23andMe a traité 12,1 millions de tests génétiques des clients au troisième trimestre 2023. La plate-forme numérique génère 308,4 millions de dollars de revenus annuels avec un taux d'interaction en libre-service numérique de 68%.

Métrique de la plate-forme	2023 données
Comptes clients totaux	14,3 millions
Taux d'engagement de la plate-forme numérique	68%
Durée moyenne de la session utilisateur	22 minutes

Rapports génétiques personnalisés

23andMe fournit 6 rapports de risques génétiques à santé génétiques distincts et 12 rapports d'état de transporteur génétique via sa plate-forme.

• Rapports de prédisposition de la santé: 6 catégories
• Rapports d'état du transporteur: 12 conditions génétiques
• Rapports de composition d'ascendance: couvrant plus de 2 000 régions géographiques

Support client et conseil génétique

Canal de support	Performance annuelle
Assistance de chat en ligne	Taux de satisfaction du client à 94%
Temps de réponse de la prise en charge de l'e-mail	Moins de 24 heures
Séances de conseil génétique	3 500 consultations annuelles

Engagement communautaire numérique

La plate-forme de recherche de 23andMe implique 80% des clients dans des programmes de recherche facultatifs, avec 500 000 participants à la recherche actifs.

Mises à jour continues d'informations génétiques

La société fournit des mises à jour trimestrielles sur le rapport génétique, avec une moyenne de 37 nouvelles informations génétiques ajoutées chaque année aux profils d'utilisateurs individuels.

Mettre à jour la métrique	Performance annuelle
Mises à jour du rapport génétique	4 mises à jour trimestrielles
Nouvelles idées génétiques	37 par utilisateur profile
Idées axées sur la recherche	85% dérivé de la participation à la recherche client

23andMe Holding Co. (ME) - Modèle commercial: canaux

Plate-forme en ligne directe aux consommateurs

23andMe exploite une plate-forme en ligne directe aux consommateurs avec 6,8 millions de clients au T3 2023. La plate-forme a généré 243 millions de dollars de revenus en 2022.

Métrique de la plate-forme	Valeur
Total des clients	6,8 millions
Revenus annuels (2022)	243 millions de dollars
Trafic	3,5 millions de visiteurs mensuels

Application mobile

L'application mobile 23andMe a été téléchargée 2,1 millions de fois avec une cote de 4,5 / 5 sur les magasins d'applications.

• Compatibilité iOS et Android
• Rapports sur les risques de santé génétique en temps réel
• Taux d'engagement des utilisateurs: 68%

Site Web de commerce électronique

23andMe.com traite environ 175 000 commandes de tests génétiques par an avec une valeur de commande moyenne de 129 $.

Marketing numérique

Canal numérique	Atteindre
Abonnés Facebook	285,000
Fondeurs Instagram	142,000
Dépenses publicitaires numériques (2022)	37,6 millions de dollars

Partenariats et pharmacies de vente au détail

23andMe a des partenariats avec certains emplacements de vente au détail, notamment CVS et Walgreens, représentant environ 15% de leur canal de vente total.

• CVS Health Partnership Emplacements: 9 500 magasins
• Emplacements de partenariat Walgreens: 8 965 magasins
• Contribution du canal de vente au détail: 36,5 millions de dollars en 2022

23andme Holding Co. (ME) - Modèle d'entreprise: segments de clientèle

Personnes soucieuses de la santé

Au quatrième trimestre 2023, 23andMe a déclaré 14,3 millions de clients au total, avec environ 5,6 millions de clients actifs intéressés par les tests génétiques liés à la santé.

Client démographique	Pourcentage	Tranche d’âge moyen
Segment soucieux de sa santé	39.2%	35 à 54 ans

Antffions de généalogie

La base de données d'ascendance de 23andMe contient des informations génétiques de plus de 12,7 millions d'individus en décembre 2023.

• Généalogie Test Kit Prix: 99 $ - 199 $
• Dépenses moyennes des clients pour la recherche sur les ascendances: 129,50 $

Personnes intéressées par l'ascendance génétique

En 2023, les tests d'ascendance génétique représentaient 42% de la clientèle totale de 23andMe.

Distribution géographique	Pourcentage d'utilisateurs
États-Unis	68%
Canada	12%
Pays européens	15%

Participants à la recherche

Le programme de recherche de 23andMe comprend 80% des clients qui ont consenti à participer à des études de recherche génétique.

• Nombre de participants à la recherche: 11,4 millions
• Partenariats de recherche: 50+ institutions pharmaceutiques et universitaires

Consommateurs de soins de santé proactifs

Les tests génétiques liés aux soins de santé représentaient 33% du total des segments de clients de 23andMe en 2023.

Type d'évaluation des risques pour la santé	Pourcentage d'utilisateurs
Risque de cancer	22%
Prédispositions de santé génétique	45%
Statut du transporteur	33%

23andMe Holding Co. (ME) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, 23andMe a déclaré des frais de recherche et de développement de 109,7 millions de dollars.

Exercice fiscal	Dépenses de R&D	Pourcentage de revenus
2023	109,7 millions de dollars	78.3%
2022	126,5 millions de dollars	82.1%

Maintenance des infrastructures technologiques

L'infrastructure technologique annuelle et les coûts de cloud computing étaient d'environ 15,2 millions de dollars en 2023.

• Dépenses de service cloud: 8,7 millions de dollars
• Maintenance matérielle: 4,5 millions de dollars
• Licence de logiciel: 2 millions de dollars

Tests et traitement en laboratoire

Les coûts d'exploitation de laboratoire pour 2023 ont totalisé 42,3 millions de dollars.

Catégorie de coûts	Montant
Entretien de l'équipement	18,6 millions de dollars
Matériaux consommables	14,2 millions de dollars
Salaires du personnel de laboratoire	9,5 millions de dollars

Marketing et acquisition de clients

Les frais de marketing pour 2023 étaient de 37,8 millions de dollars.

• Publicité numérique: 22,5 millions de dollars
• Campagnes promotionnelles: 9,3 millions de dollars
• Programmes de référence client: 6 millions de dollars

Sécurité des données et gestion de la conformité

Les coûts de conformité et de sécurité des données en 2023 s'élevaient à 12,4 millions de dollars.

Catégorie de dépenses de sécurité	Montant
Infrastructure de cybersécurité	6,2 millions de dollars
Conformité réglementaire	4,7 millions de dollars
Conseil de protection des données	1,5 million de dollars

23andMe Holding Co. (ME) - Modèle commercial: Strots de revenus

Ventes de kit de test ADN

Au troisième trimestre 2023, 23andMe a déclaré 6,4 millions de clients cumulatifs. Prix ​​moyen du kit de test ADN: 99 $ - 229 $.

Type de produit	Fourchette	Estimation annuelle des revenus
Kit d'ascendance	$99	50-75 millions de dollars
Kit de santé + d'ascendance	$229	100 à 150 millions de dollars

Rapports de santé génétiques

23andMe propose des rapports de risques génétiques sur la santé entre 99 $ et 199 $. Renus du rapport de santé en 2022: 43,4 millions de dollars.

Partenariats de recherche pharmaceutique

Les partenariats pharmaceutiques clés comprennent:

• GSK (GlaxoSmithKline): 300 millions de dollars d'investissement initial en 2018
• Almirall: Collaboration pour la recherche sur le traitement du psoriasis
• Genentech: partenariats de recherche génétique

Licence de données génétiques anonymisées

Revenus de licence de données génétiques pour 2022: environ 22,3 millions de dollars.

Type de données	Gamme de prix de licence	Revenus annuels
Données génétiques anonymisées	50 $ - 500 $ par ensemble de données	15-25 millions de dollars

Services de connaissances génétiques basées sur l'abonnement

23andMe a lancé un service d'abonnement premium en 2023. Prix d'abonnement: 29,99 $ - 49,99 $ par an.

• Abonnés estimés: 50 000 à 100 000
• Revenu annuel d'abonnement: 1,5 à 5 millions de dollars

23andMe Holding Co. (ME) - Canvas Business Model: Value Propositions

Personalized health and ancestry insights from a single saliva test remain the core value proposition for 23andMe Holding Co. The company provides reports based on genotyping, which includes Ancestry Composition, Ancestry Detail Reports, Maternal & Paternal Haplogroups, and Neanderthal Ancestry. The service is the first and only direct-to-consumer DNA service with multiple health reports that have received FDA clearance.

The shift toward recurring revenue is a key part of the current model. In the second quarter of fiscal year 2025, subscription revenue accounted for 21% of total revenue, more than double the 9% recorded in the prior-year quarter. This recurring stream is driven by the 23andMe+ tiers, which offer ongoing reports and features.

Membership Tier	Key Features/Reports	Renewal Price (Annual)
23andMe+ Premium	100+ genetic insights, Health action tools, Advanced Ancestry insights	$69/yr
23andMe+ Total Health	Exome sequencing, Biannual blood testing (55+ biomarkers), Clinician access, Biological Age tracking	$499/yr

Telehealth access is expanding to offer genetics-informed preventive care. 23andMe Holding Co. announced the initiation of a large-scale genetic research study to pinpoint the genetic factors driving the efficacy and side effects of GLP-1 medications. Furthermore, the company planned to launch a GLP-1 weight loss telehealth membership on the Lemonaid Health platform by the end of the month following Q1 FY25 results, enabling members to receive prescriptions for brand-name or compounded semaglutide medications.

The unparalleled scale of genetic data is the backbone for biopharma drug target identification, even after the end of the exclusive collaboration term with GlaxoSmithKline (GSK) in July 2023. The company's research platform is built on the genetic data of over 15 million genotyped individuals. This massive dataset is considered a 'gold mine' for identifying genetic associations with diseases and traits, supporting drug discovery efforts.

Democratizing access to genetic information is supported by the sheer volume of users and the depth of reporting available. The database holds the genetic data of 15 million people. The Total Health offering enhances this by including exome sequencing, which analyzes a portion of DNA to detect 200x more disease-causing variants compared to standard genotyping.

• The company's Q3 FY25 Consumer Services Revenue was $39.6 million.
• PGS membership services revenue grew by $4.6 million in Q3 FY25 compared to the prior year quarter.
• Total Health members receive analysis of 55+ blood biomarkers.
• Members have access to over 30 genetic Polygenic Risk Score (PRS) reports.

Finance: draft 13-week cash view by Friday.

23andMe Holding Co. (ME) - Canvas Business Model: Customer Relationships

The relationship with the consumer base for 23andMe Holding Co. centers on a mix of automated digital interaction, recurring membership value, and high-touch research collaboration.

Automated, self-service platform for initial kit purchase and results delivery.

The initial customer acquisition relies on the direct-to-consumer model, though Consumer Services Revenue saw a decrease, with revenue of $39.6 million in Q3 of FY25 compared to $42.9 million in Q3 of FY24. This decrease was driven by a $6.4 million drop in PGS revenue due to lower kit sales volume and lower average selling prices for kits. As of March 31, 2024, 23andMe Holding Co. had approximately 15.1 million customers. Following the 2023 cyber incident, the class action settlement alleged exposure of personal and genetic information for about 6.4 million U.S. customers.

Subscription-based, continuous engagement for 23andMe+ Premium and Total Health members.

23andMe Holding Co. is actively prioritizing recurring revenue streams to stabilize the business model, which historically relied on one-time kit purchases. Membership services revenue growth is a key focus area, having more than doubled from the prior year quarter in Q2 FY25.

Metric	Value/Period	Context/Date
Membership Services Revenue Share of Total Revenue	21%	Q2 Fiscal Year 2025 (FY25 Q2)
Membership Services Revenue Share of Total Revenue (Prior Year)	9%	Q2 Fiscal Year 2024 (FY24 Q2)
Growth in PGS Membership Services Revenue	$4.6 million	Q3 FY25 vs. Q3 FY24
Total Health Key Biomarkers	55+	Bi-annual lab tests included
Available Genetic Polygenic Risk Score (PRS) Reports	Over 30	For 23andMe+ members

The Total Health offering now includes a Biological Age feature for members to monitor physiological aging over time.

Dedicated Customer Care Team for support and inquiries.

Customer support interactions are necessary, especially given past events affecting trust. Anecdotal customer feedback from early 2025 suggested that calling the customer service line resulted in repeating prompts, though the chat function was reported as 'ok' even with a queue of 41 people. The company is also managing claims related to the 2023 data breach, with a total settlement fund of $50,000,000.

AI chatbot DaNA for easier interpretation of health results.

23andMe Holding Co. launched its first AI chatbot, named "DaNA," to help customers more easily identify key health and other important results from their genetic data.

High-touch, B2B relationship management for research and biopharma partners.

The research partnership business remains a focus, though its revenue contribution is currently small following the conclusion of the GSK collaboration exclusivity term in July 2023. Research services revenue accounted for approximately 3% of total revenue for FY25 Q1. In Q3 FY25, 23andMe Holding Co. recognized $19.3 million of non-recurring research services revenue related to the 2023 GSK Amendment. The company also launched a GLP-1 weight loss telehealth membership on the Lemonaid Health platform, enabling prescription of semaglutide medications.

• The company implemented a 40% reduction in force with anticipated cost savings of more than $35 million annually.
• The company announced a collaboration with Nightingale Health to pilot a metabolomics blood biomarker panel with a cohort of 23andMe+ members.

Finance: draft 13-week cash view by Friday.

23andMe Holding Co. (ME) - Canvas Business Model: Channels

You're looking at the channels for 23andMe Holding Co. (ME) as the company navigated a Chapter 11 bankruptcy filing in March 2025 and subsequent asset acquisition by TTAM Research Institute in July 2025. The channels reflect a business model under severe transition, focusing on recurring revenue streams while core transactional sales declined.

Direct-to-Consumer (DTC) e-commerce via the 23andMe website

The primary historical channel for Personal Genome Service (PGS) kit sales and subscription services remains the 23andMe website. However, the financial performance shows strain on this direct channel.

For the third quarter of fiscal year 2025 (FY25 Q3), which ended December 31, 2024, Consumer Services Revenue-which includes PGS kits and membership services-was $39.6 million, marking an 8% decrease compared to the prior year quarter's $42.9 million. This decline was specifically attributed to lower kit sales volume and lower average selling prices for the PGS product line.

The strategic pivot focused on recurring revenue is evident here:

• Membership services revenue growth partially offset the decline in transactional PGS revenue.
• Membership services revenue represented 21% of total revenue in Q2 FY25.
• This was a significant increase from representing only 9% of total revenue in the prior year quarter (Q2 FY24).

As of September 30, 2024, 23andMe had accumulated approximately 15.1 million customers across all services.

Retail stores (physical and online) for PGS kit sales

While the DTC website is central, retail presence supports broader market penetration. The performance across geographic markets, which utilize these channels, showed divergence in late 2024.

Geographic revenue performance for the three months ended December 31, 2024, highlights channel effectiveness outside the core US DTC site:

Region	Revenue Change (YoY)	Context
United Kingdom	Increase of 903.23%	Significant market expansion or one-time event.
Canada	Decrease of approximately 32.91%	Underperformance in that specific retail/online market.

The United States remains the major market, holding approximately 55% of the US consumer genomics market share in 2025.

Lemonaid Health mobile app and web platform for telehealth services

The Lemonaid Health platform served as a key channel for telehealth services, including the launch of a GLP-1 weight loss membership in late 2024. However, the channel's future was curtailed following the bankruptcy proceedings.

The service was explicitly noted as not part of the sale to Regeneron Pharmaceuticals in May 2025, and 23andMe stated it would be wound down. Telehealth revenue specifically saw a decrease of $1.5 million in FY25 Q3 compared to the prior year quarter.

Scientific conferences (e.g., NeurIPS 2025) for research dissemination and partner acquisition

This channel is less about direct sales and more about B2B/Research Services engagement, crucial for leveraging the genetic database post-GSK collaboration. While specific 2025 conference attendance numbers aren't public, the research dissemination efforts continued into late 2025 under the new ownership structure.

Research dissemination activities reported in late 2024/early 2025 included:

• Presenting posters for therapeutics programs 23ME-00610 and 23ME-01473 at the American Association for Cancer Research (AACR) annual meeting.
• Publishing a large genetic study on sickle cell trait in collaboration with the National Institutes of Health and Johns Hopkins University School of Medicine.
• Launching a large-scale lung cancer study aiming to enroll 10,000 patients, having already enrolled more than 1,000 as of late 2024.
• The research institute later released data on over 250+ High-Resolution African Genetic Groups in November 2025.

Research services revenue was minimal, accounting for approximately 3% of total revenue in Q1 FY25.

23andMe Holding Co. (ME) - Canvas Business Model: Customer Segments

You're looking at the core groups 23andMe Holding Co. (ME) targets to generate revenue and data assets in late 2025. The customer base is definitely split between direct consumers and institutional partners.

Direct-to-Consumer (DTC) individuals, typically aged 35-65, interested in ancestry and health.

The Personal Genome Service (PGS) kit sales remain a primary driver, though facing headwinds. Consumer services, which bundle PGS, telehealth, and membership, represented approximately 97% of total revenue in Q1 Fiscal Year 2025 (ending June 30, 2024). However, Q3 Fiscal Year 2025 (ending December 31, 2024) saw Consumer Services Revenue at $39.6 million, an 8% lower figure compared to the prior year quarter. This decline was driven by a $6.4 million decrease in PGS revenue due to lower kit sales volumes and lower average selling prices. Geographically, the United States accounts for approximately 55% of the direct-to-consumer genetic testing market share in 2025, while North America holds a 46.7% share of the global consumer genomics market for the same year. The company has faced significant retention challenges, with many customers purchasing the kit only once.

The company's customer base is also segmented by their engagement level, moving toward recurring revenue:

• Access to over 30 genetic Polygenic Risk Score (PRS) reports is available to members.
• Membership services revenue grew by $4.6 million in Q3 FY25 compared to the prior year period.
• Membership services represented 21% of total revenue in Q2 FY25, up from 9% in the prior year quarter.
• The 23andMe+ Premium annual membership price was reported at $69.
• The Total Health offering includes exome sequencing and biannual blood testing.

Biopharmaceutical companies and research institutions seeking genetic data for R&D.

This segment, categorized as Research Services revenue, accounted for only about 3% of total revenue for Q1 FY25. The prior year's revenue was significantly impacted by the conclusion of the exclusive collaboration term with GSK in July 2023. Under a 2023 amendment, GSK paid $20 million for a one-year license to the database insights. The initial high-profile partnership with GSK involved a $300 million equity investment. However, as of Q3 FY25 reporting, 23andMe Holding Co. discontinued its Therapeutics business to reduce expenses.

Here's a quick look at the financial context surrounding the research segment:

Metric	Value (Q1 FY25 Ending 6/30/2024)	Value (Q3 FY25 Ending 12/31/2024)
Total Revenue	$40 million	$60.3 million
Research Services Revenue Share	Approximately 3%	Non-recurring revenue recognized: $19.3 million
Cash and Cash Equivalents	$170 million (as of 6/30/2024)	$79.4 million (as of 12/31/2024)

Telehealth users seeking convenient, genetics-informed medical care, defintely for weight loss.

The Lemonaid Health platform supports the Telehealth offering within the Consumer & Research Services segment. Telehealth orders contributed to lower consumer revenue in Q1 FY25. Specifically, Telehealth revenue saw a $1.5 million decrease in Q3 FY25 compared to the prior year quarter. The company announced plans to launch a GLP-1 weight loss telehealth membership on the Lemonaid Health platform by the end of August 2024, allowing members to be prescribed semaglutide medications.

23andMe Holding Co. (ME) - Canvas Business Model: Cost Structure

You're looking at the hard costs 23andMe Holding Co. (ME) is managing as it pivots its focus. The cost structure reflects a significant shift away from high-risk, high-cost ventures toward core consumer services and data monetization.

High Cost of Revenue for PGS Kits (Lab Processing, Materials, Shipping)

The core Personal Genome Service (PGS) kit business carries inherent variable costs tied directly to volume. While specific Cost of Goods Sold (COGS) for kits isn't explicitly broken out in the latest reports, the impact on revenue is clear. For the third quarter of Fiscal Year 2025 (FY25 Q3), Consumer Services Revenue, which includes PGS, Telehealth, and membership, was 39.6 million USD, an 8% decline year-over-year. This decline was driven by a 6.4 million USD decrease in PGS revenue alone, attributed to lower kit sales volume and lower average selling prices. This shows that the cost to produce, process, and ship these kits directly pressures the gross profit margin when sales volume drops.

Significant Reduction in Research and Development (R&D) Expenses After Discontinuing Therapeutics

The decision to discontinue the Therapeutics division was a major cost-cutting measure. This move was intended to reduce expenses significantly, especially R&D spend previously associated with drug development. For FY25 Q3, the net loss from discontinued operations (Therapeutics) was 18.8 million USD. This was partially offset by lower personnel-related expenses and a significantly reduced lab-related R&D spend. The shift meant opting for a royalty structure on certain GSK partnered programs, leading to a significant reduction in collaboration expenses compared to prior periods.

Operating Expenses Reduced by a 40% Workforce Reduction

The company aggressively streamlined its overhead. 23andMe Holding Co. implemented a 40% reduction in force, cutting about 200 positions. This restructuring was designed to achieve annualized cost savings of more than 35 million USD annually. The impact on reported operating expenses is stark when comparing recent quarters to the prior year. Operating expenses for FY25 Q3 were 68.2 million USD, a massive drop from 282.6 million USD in the same period the prior year. Even looking at Q2 FY25, operating expenses were 84 million USD, down from 101 million USD the prior year. These personnel-related savings, including non-cash stock-based compensation expenses, were the primary driver for the reduction. However, this came with one-time costs, with the company expecting to incur approximately 12 million USD primarily related to severance and termination costs.

Legal and Settlement Costs Related to the 2023 Data Security Incident

The fallout from the 2023 data security incident created a material liability. The total proposed U.S. class-action settlement fund was increased to 50 million USD, up from an initial 30 million USD. This 50 million USD settlement received preliminary approval from a Missouri bankruptcy court on September 5, 2025. Separately, a proposed Canadian class-action settlement was reported at approximately 4.49 million CAD, or 3.25 million USD before legal fees.

Marketing and Sales Expenses to Drive Consumer Kit Sales and Subscription Growth

While marketing spend was reduced in Fiscal Year 2024 to boost margin, the current focus is on driving higher-margin recurring revenue. Membership services revenue growth is a key counterpoint to falling kit sales. In FY25 Q2, membership services revenue increased, representing 21% of total revenue, up from 9% in the prior year quarter. This indicates a strategic shift in spending priorities toward customer retention and subscription value rather than purely top-of-funnel kit acquisition, though marketing spend remains a component of operating expenses.

Here's a quick look at the key cost structure movements for recent quarters:

Metric	FY25 Q1 Value (USD)	FY25 Q2 Value (USD)	FY25 Q3 Value (USD)
Operating Expenses	92 million	84 million	68.2 million
Prior Year Operating Expenses	140 million	101 million	282.6 million
Annualized Cost Savings from Workforce Reduction	More than 35 million
One-Time Restructuring Costs	Approximately 12 million

23andMe Holding Co. (ME) - Canvas Business Model: Revenue Streams

You're looking at the revenue streams for 23andMe Holding Co. (ME) as of late 2025, focusing on the most recent reported figures from fiscal year 2025. The business model is clearly shifting focus toward more predictable, higher-margin recurring revenue, though one-time research milestones still provide significant boosts.

The Personal Genome Service (PGS) kit sales remain a core, albeit volatile, component, representing the one-time revenue stream from new customer acquisition. For the third quarter of fiscal year 2025 (FY25 Q3), which ended December 31, 2024, the revenue from PGS itself saw a decline. Specifically, PGS revenue dropped by $6.4 million compared to the prior year quarter, driven by lower kit sales volume and lower average selling prices for the kits.

The pivot to recurring revenue is evident in the subscription segment. Subscription revenue from 23andMe+ membership services showed strong growth momentum. In the second quarter of fiscal year 2025 (FY25 Q2), membership services revenue grew to represent 21% of total revenue, up from 9% in the prior year quarter. This focus continued into Q3 FY25, where PGS membership services revenue grew by $4.6 million year-over-year, partially offsetting the decline in one-time PGS sales and Telehealth.

Research services revenue is characterized by large, non-recurring milestone payments, though the company has since restructured its Therapeutics arm. For FY25 Q3, 23andMe recognized $19.3 million of non-recurring research services revenue pursuant to the 2023 GSK Amendment. This amount represented substantially all remaining revenue associated with that amendment, and the cash for this was actually received in Q3 FY24. The company has since discontinued its Therapeutics business to reduce expenses, opting instead for a royalty structure on partnered drug programs.

Telehealth service fees via the Lemonaid Health platform also contribute to consumer services revenue, but this stream also faced headwinds. In FY25 Q3, Telehealth revenue saw a decrease of $1.5 million compared to the prior year quarter due to lower orders. The company had announced plans to launch a GLP-1 weight loss telehealth membership on the Lemonaid Health platform by the end of Q1 FY25.

Here's a quick look at the key revenue components from the Q3 FY25 results, showing the impact of the non-recurring research event:

Revenue Stream Category	FY25 Q3 Amount (USD)	Year-over-Year Change/Note
Total Revenue	$60.3 million	Up 35% YoY (driven by non-recurring event)
Consumer Services Revenue (Total)	$39.6 million	Down 8% YoY
PGS Membership Services Revenue Growth	$4.6 million	Increase YoY
Non-Recurring Research Services Revenue (GSK)	$19.3 million	Recognized in Q3 FY25
PGS Revenue Change (Component of Consumer)	Decrease of $6.4 million	Due to lower kit sales/ASPs
Telehealth Revenue Change (Component of Consumer)	Decrease of $1.5 million	Due to lower orders

The company's strategy emphasizes the shift to recurring revenue streams, as evidenced by the growth in membership services, even as the one-time kit sales and research milestones fluctuate. The structure now relies on:

• Personal Genome Service (PGS) kit sales (one-time revenue).
• Subscription revenue from 23andMe+ membership services, which hit 21% of total revenue in Q2 FY25.
• Research services revenue from biopharma partnerships, including the $19.3 million non-recurring recognition in Q3 FY25.
• Telehealth service fees via the Lemonaid Health platform.
• Royalty payments from partnered drug programs (post-restructuring).

Finance: draft 13-week cash view by Friday.